Meet Our Leadership
Catestatin
Catestatin (CST) is a naturally occurring, 21-amino-acid bioactive peptide derived from the neuroendocrine secretory protein chromogranin A (CgA). Originally discovered as an endogenous inhibitor of nicotinic cholinergic-stimulated catecholamine release, CST has subsequently emerged as a multifunctional regulatory peptide with important actions in cardiovascular, metabolic, immune, gastrointestinal, and nervous-system physiology.
Read MorePatents & Intellectual Property
CgA Therapeuticals is building an intellectual property portfolio centered on catestatin (CST), next-generation CST-based peptides and peptidomimetics, Boolean implication network technologies, and related therapeutic and computational innovations.
The company has entered into an exclusive license agreement with The Regents of the University of California, represented by UC San Diego, covering defined patent rights for specified therapeutic technologies.
Read MoreTherapeutic Platform
CgA Therapeuticals is developing catestatin (CST) and next-generation CST-based peptides and peptidomimetics as potential therapeutics for diseases involving dysregulated neuroendocrine signaling, inflammation, metabolism, gastrointestinal function, cardiovascular homeostasis, and neurodegeneration.
Rather than acting through a single disease-associated pathway, CST influences multiple interconnected biological processes involved in maintaining physiological homeostasis, providing the scientific foundation for a platform-based therapeutic strategy across multiple areas of unmet medical need.
Read MoreFederal Research Support
CgA Therapeuticals' therapeutic programs are supported by a foundation of federally funded research investigating catestatin (CST), chromogranin A (CgA), aging, neurodegeneration, gastrointestinal dysfunction, metabolic disease, and related therapeutic applications. Current and selected prior awards relevant to the scientific development of the CST therapeutic platform are highlighted below.
Current Research Support
NIH/NIDDK SBIR Phase I
Peptide and Peptidomimetic Therapy for Gastroparesis
CgA Therapeuticals, Inc. | 2026–2027
Award No. 1R43DK148298-01 | Total Award: $350,195
Supports the preclinical development of CST and CST-based peptidomimetics as potential therapies for gastroparesis.